UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Inhibition of EZH2 Catalytic Activity Selectively Targets a Metastatic Subpopulation in Triple-Negative Breast Cancer

Cell reports (Cambridge), 2020-01, Vol.30 (3), p.755-770.e6

2020

Volltextzugriff (PDF)

Alterations of the 70 kDa heat shock protein (HSP70) and sequestosome-1 (p62) in women with breast cancer

Scientific reports, 2021-11, Vol.11 (1), p.22220-22220, Article 22220

2021

Volltextzugriff (PDF)

Tetrathiomolybdate (TM)-associated copper depletion influences collagen remodeling and immune response in the pre-metastatic niche of breast cancer

NPJ breast cancer, 2021-08, Vol.7 (1), p.108-108, Article 108

2021

Volltextzugriff (PDF)

Phase I/II trial of ruxolitinib in combination with trastuzumab in metastatic HER2 positive breast cancer

Breast cancer research and treatment, 2021-08, Vol.189 (1), p.177-185

2021

Volltextzugriff (PDF)

Benefit of adjuvant chemotherapy in node-negative T1a versus T1b and T1c triple-negative breast cancer

Breast cancer research and treatment, 2022-02, Vol.192 (1), p.163-173

2022

Volltextzugriff (PDF)

Facts and Perspectives: Implications of tumor glycolysis on immunotherapy response in triple negative breast cancer

Frontiers in oncology, 2023-01, Vol.12, p.1061789-1061789

2023

Volltextzugriff (PDF)

Three-dimensional growth of breast cancer cells potentiates the anti-tumor effects of unacylated ghrelin and AZP-531

eLife, 2020-07, Vol.9

2020

Volltextzugriff (PDF)

Circulating Tumor Cells and [18F]Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Outcome Prediction in Metastatic Breast Cancer

Journal of clinical oncology, 2009-07, Vol.27 (20), p.3303-3311

2009

Volltextzugriff (PDF)

Assessment of an RNA interference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast cancer: a retrospective analysis of five clinical trials

The lancet oncology, 2010-04, Vol.11 (4), p.358-365

2010

Volltextzugriff (PDF)

A phase I-II study of the histone deacetylase inhibitor vorinostat plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in locally advanced breast cancer

Breast cancer research and treatment, 2014-07, Vol.146 (1), p.145-152

2014

Volltextzugriff (PDF)

Akt Inhibition Is Associated With Favorable Immune Profile Changes Within the Tumor Microenvironment of Hormone Receptor Positive, HER2 Negative Breast Cancer

Frontiers in oncology, 2020-06, Vol.10

2020

Volltextzugriff (PDF)

SETER/PR: a robust 18-gene predictor for sensitivity to endocrine therapy for metastatic breast cancer

NPJ breast cancer, 2019-05, Vol.5 (1), p.16, Article 16

2019

Volltextzugriff (PDF)

Phase I–II study of the farnesyl transferase inhibitor tipifarnib plus sequential weekly paclitaxel and doxorubicin–cyclophosphamide in HER2/neu-negative inflammatory carcinoma and non-inflammatory estrogen receptor-positive breast carcinoma

Breast cancer research and treatment, 2013-10, Vol.141 (3), p.429-435

2013

Volltextzugriff (PDF)

Impact of HER2 low expression in the Oncotype DX RS in patients with operable hormone receptor positive early stage breast cancer

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.575-575

2023

Volltextzugriff (PDF)

Eribulin Plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase Ib/II Study

Clinical cancer research, 2021-06, Vol.27 (11), p.3061-3068

2021

Volltextzugriff (PDF)

Therapies for triple negative breast cancer

Expert opinion on pharmacotherapy, 2015-05, Vol.16 (7), p.983-998

2015

Volltextzugriff (PDF)

A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer

JAMA : the journal of the American Medical Association, 2011-05, Vol.305 (18), p.1873

2011

Volltextzugriff (PDF)

Endocrine Therapy-related Endocrinopathies—Biology, Prevalence, and Implications for the Management of Breast Cancer

Oncology & Hematology Review (US), 2020, Vol.16 (1), p.17

2020

Volltextzugriff (PDF)

Circulating tumor cells as prognostic marker in metastatic breast cancer

Expert review of anticancer therapy, 2010-02, Vol.10 (2), p.171-177

2010

Volltextzugriff (PDF)

Differential genomic profiling of the progesterone receptor (PR) negative and estrogen receptor (ER) low metastatic breast cancer subtypes through circulating tumor DNA: A TNBC -like disease subtype?

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.1039-1039

2024

Volltextzugriff (PDF)

Targeting insulin feedback to enhance alpelisib (TIFA): A phase II randomized trial in metastatic, PIK3CA -mutant, hormone receptor–positive breast cancer

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS1113-TPS1113

2022

Volltextzugriff (PDF)

Preliminary report of a phase 1b/2a trial, an oral inhibitor of phosphorylated P68 (P-p68) which mediates β-catenin nuclear translocation in advanced triple-negative breast cancer (TNBC)

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.1097-1097

2018

Volltextzugriff (PDF)

Phase III Randomized, Placebo-Controlled Trial of Endocrine Therapy ± 1 Year of Everolimus in Patients With High-Risk, Hormone Receptor–Positive, Early-Stage Breast Cancer

Journal of clinical oncology, 2024-09, Vol.42 (25), p.3012-3021

2024

Volltextzugriff (PDF)

Characterization of metastatic breast cancer patients with nondetectable circulating tumor cells

International journal of cancer, 2011-07, Vol.129 (2), p.417-423

2011

Volltextzugriff (PDF)

1 – 25 von 104

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(97)
Mit Volltextzugriff
(88)

Publikationsform

Artikel
(102)
Buchkapitel
(2)

Sprache

Englisch
(104)

Erscheinungsjahr

n.n

Thema

Science & Technology
(57)
Life Sciences & Biomedicine
(56)
Oncology
(42)
Humans
(33)
Female
(30)
Breast Cancer
(27)
Middle Aged
(19)
Adult
(17)
Breast Neoplasms - Pathology
(16)
Aged
(15)
Tumors
(13)
Breast Neoplasms - Drug Therapy
(12)
Medicine
(11)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(10)
Biological And Medical Sciences
(10)
Medical Sciences
(10)
Medicine & Public Health
(10)
Cancer Research
(9)
Gynecology. Andrology. Obstetrics
(9)
Breast Neoplasms - Genetics
(8)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Inhibition of EZH2 Catalytic Activity Selectively Targets a Metastatic Subpopulation in Triple-Negative Breast Cancer

Alterations of the 70 kDa heat shock protein (HSP70) and sequestosome-1 (p62) in women with breast cancer

Tetrathiomolybdate (TM)-associated copper depletion influences collagen remodeling and immune response in the pre-metastatic niche of breast cancer

Phase I/II trial of ruxolitinib in combination with trastuzumab in metastatic HER2 positive breast cancer

Benefit of adjuvant chemotherapy in node-negative T1a versus T1b and T1c triple-negative breast cancer

Facts and Perspectives: Implications of tumor glycolysis on immunotherapy response in triple negative breast cancer

Three-dimensional growth of breast cancer cells potentiates the anti-tumor effects of unacylated ghrelin and AZP-531

Circulating Tumor Cells and [18F]Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Outcome Prediction in Metastatic Breast Cancer

Assessment of an RNA interference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast cancer: a retrospective analysis of five clinical trials

A phase I-II study of the histone deacetylase inhibitor vorinostat plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in locally advanced breast cancer

Akt Inhibition Is Associated With Favorable Immune Profile Changes Within the Tumor Microenvironment of Hormone Receptor Positive, HER2 Negative Breast Cancer

SETER/PR: a robust 18-gene predictor for sensitivity to endocrine therapy for metastatic breast cancer

Phase I–II study of the farnesyl transferase inhibitor tipifarnib plus sequential weekly paclitaxel and doxorubicin–cyclophosphamide in HER2/neu-negative inflammatory carcinoma and non-inflammatory estrogen receptor-positive breast carcinoma

Impact of HER2 low expression in the Oncotype DX RS in patients with operable hormone receptor positive early stage breast cancer

Eribulin Plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase Ib/II Study

Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: MAINTAIN Trial

Therapies for triple negative breast cancer

A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer

Endocrine Therapy-related Endocrinopathies—Biology, Prevalence, and Implications for the Management of Breast Cancer

Circulating tumor cells as prognostic marker in metastatic breast cancer

Differential genomic profiling of the progesterone receptor (PR) negative and estrogen receptor (ER) low metastatic breast cancer subtypes through circulating tumor DNA: A TNBC -like disease subtype?

Targeting insulin feedback to enhance alpelisib (TIFA): A phase II randomized trial in metastatic, PIK3CA -mutant, hormone receptor–positive breast cancer

Preliminary report of a phase 1b/2a trial, an oral inhibitor of phosphorylated P68 (P-p68) which mediates β-catenin nuclear translocation in advanced triple-negative breast cancer (TNBC)

Phase III Randomized, Placebo-Controlled Trial of Endocrine Therapy ± 1 Year of Everolimus in Patients With High-Risk, Hormone Receptor–Positive, Early-Stage Breast Cancer

Characterization of metastatic breast cancer patients with nondetectable circulating tumor cells

Suchergebnisse filtern